Gapping down
In reaction to disappointing earnings/guidance: CRNT -6.2% (also announces public offering of its ordinary share), SOHU -5.6%, HIHO -4.2%, SKYW -3.6%, TSN -1.4%, CYOU -0.6%, CMI -0.5%, TGE -0.4%.
M&A news: DG DG -2.9% (potentially related to FDO/DLTR news, less likely to be acquired), BRKR -2.6% (announces acquisition of Vutara)
Select solar names showing weakness after news that US has decided on new anti-dumping duties on imports of solar products from China: JKS -4.1%, YGE -4%, CSIQ -3.4%, JASO -2.5%, TSL -2.3%.
Other news: HZNP -36% (disclosed that it has been notified that in August 2014 CVS Caremark (CVS) and Express Scripts (ESRX) expect to announce DUEXIS and VIMOVO will no longer be on their formularies), ACRX -26.8% (receives Complete Response Letter from FDA for New Drug Application for Zalviso), JMEI -8.3% (no known catalyst, pulling back following recent strength), TRLA-5.1% (cautious Citron report out over the weekend), RBS -3.1% (plans to sell Ulster Bank stake, according to reports), BIOD -2.9% (enters into $15 mln equity commitment with Lincoln Park Capital), YNDX -1.8% (Russian Micex down 1%), BLDR -1.7% (negative mention Mad Money), CCL -1.1% (still checking), SDRL -0.9% (announces result of voluntary incentive offer to convert the $650 mln of 3.375% 2017 convertible bond), DNKN -0.7% (negative mention Mad Money), Z -0.6% (cautious Citron report out over the weekend), BSX -0.5% (JNJ and BSX dispute over deal to go to trail, according to reports), .
Analyst comments: TRP -1.5% (downgraded to Neutral from Outperform at Credit Suisse), MNST -1.4% (downgraded to Neutral from Buy at UBS), PCG -1.2% (upgraded to Buy from Neutral at Goldman), CSCO -0.9% (downgraded to Sector Perform from Outperform at Pacific Crest), EE -0.9% (downgraded to Hold from Buy at Jefferies), PFE -0.5% (downgraded to Mkt Perform from Outperform at BMO Capital Mkts), COG -0.4% (downgraded to Perform at Oppenheimer).
In reaction to disappointing earnings/guidance: CRNT -6.2% (also announces public offering of its ordinary share), SOHU -5.6%, HIHO -4.2%, SKYW -3.6%, TSN -1.4%, CYOU -0.6%, CMI -0.5%, TGE -0.4%.
M&A news: DG DG -2.9% (potentially related to FDO/DLTR news, less likely to be acquired), BRKR -2.6% (announces acquisition of Vutara)
Select solar names showing weakness after news that US has decided on new anti-dumping duties on imports of solar products from China: JKS -4.1%, YGE -4%, CSIQ -3.4%, JASO -2.5%, TSL -2.3%.
Other news: HZNP -36% (disclosed that it has been notified that in August 2014 CVS Caremark (CVS) and Express Scripts (ESRX) expect to announce DUEXIS and VIMOVO will no longer be on their formularies), ACRX -26.8% (receives Complete Response Letter from FDA for New Drug Application for Zalviso), JMEI -8.3% (no known catalyst, pulling back following recent strength), TRLA-5.1% (cautious Citron report out over the weekend), RBS -3.1% (plans to sell Ulster Bank stake, according to reports), BIOD -2.9% (enters into $15 mln equity commitment with Lincoln Park Capital), YNDX -1.8% (Russian Micex down 1%), BLDR -1.7% (negative mention Mad Money), CCL -1.1% (still checking), SDRL -0.9% (announces result of voluntary incentive offer to convert the $650 mln of 3.375% 2017 convertible bond), DNKN -0.7% (negative mention Mad Money), Z -0.6% (cautious Citron report out over the weekend), BSX -0.5% (JNJ and BSX dispute over deal to go to trail, according to reports), .
Analyst comments: TRP -1.5% (downgraded to Neutral from Outperform at Credit Suisse), MNST -1.4% (downgraded to Neutral from Buy at UBS), PCG -1.2% (upgraded to Buy from Neutral at Goldman), CSCO -0.9% (downgraded to Sector Perform from Outperform at Pacific Crest), EE -0.9% (downgraded to Hold from Buy at Jefferies), PFE -0.5% (downgraded to Mkt Perform from Outperform at BMO Capital Mkts), COG -0.4% (downgraded to Perform at Oppenheimer).